Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous autosomal dominant heart disease characterised by left ventricular hypertrophy in the absence of another cardiac or systemic disease that is capable of producing significant wall thickening. Microscopically it is characterised by cardiomyocyte hypertrophy, myofibrillar disarray and fibrosis. The phenotypic expression of HCM is multifactorial, with the majority of cases occurring secondary to mutations in genes encoding the sarcomere proteins. In conjunction with the genetic heterogeneity of HCM, phenotypic expression also exhibits a high level of variability even within families with the same aetiological mutation, and may be influenced by additional genetic factors. Polymorphisms of the renin-angiotensin-aldosterone system (RAAS) represent an attractive hypothesis as potential disease modifiers, as these genetic variants alter the 'activation status' of the RAAS, which leads to more left ventricular hypertrophy through different pathways. The main objective of this review is to provide an overview of the role of different polymorphisms identified in the RAAS, in patients with HCM.
Introduction
Hypertrophic cardiomyopathy (HCM) is morphologically characterised by a marked hypertrophy of the left ventri cular wall without inciting factors such as aortic stenosis or hypertension, and microscopically by cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis. 1 HCM is a monogenic cardiac disease with an autosomal dominant pattern of heritability and different penetrance, 2 with a prevalence of 1/500 in the general population. 3 However, the prevalence of HCM is likely to be much higher in older subjects, and because the penetrance is age dependent, the affected individuals gradually exhibit the phenotype as they get older. 4 The phenotypic expression of HCM is multifac torial, with the majority of cases occurring secondary to mutations in genes encoding the sarcomere proteins. 5 More than 400 mutations in over a dozen sarcomere myofilament genes have been identified which contribute to the hetero geneity of the disease phenotype. 6 The expression, how ever, of certain mutations occurs across a vast spectrum of clinical phenotypes, 7 and further identification of risk fac tors and (genetic) modifiers continue to be a subject of intense interest. Genetic studies, in addition to establishing heterogeneity of the causal genes, have also illustrated con siderable allelic heterogeneity 8 and suggest that mutations arise independently and that there is no common founder. 9 In conjunction with the genetic heterogeneity of HCM, phenotypic expression of HCM also exhibits a high level of variability. 10 This variability can be attributable to several factors such as hypertension, 11 vigorous athletic competi tion, 12 alcohol consumption, 13 the presence of double or triple sarcomeric mutations together, 14 mutations in mito chondrial DNA such as in the Kearns-Sayre syndrome, 15 triplet repeats mutations, as happens in the myotonic mus cular dystrophy and Friedreich's ataxia, 16 or mutations in nonsarcomeric proteins.
A group of these nonsarcomeric proteins that could act as modifiers in HCM may include polymorphisms in genes encoding proteins of the renin-angiotensin-aldosterone system (RAAS). 17, 18 This system contributes to ventricular hypertrophy through effects mediated by circulating angi otensin (Ang) as well as local activation of RAAS in the myocardium. 19 Ang II, which is an octapeptide, is generated by angi otensinconverting enzyme (ACE) from Ang I (a decapep tide), which is formed by renin from angiotensinogen. 20 Ang production in the heart depends on kidneyderived renin and/or prorenin. Both are taken up from the circula tion, either through diffusion into the cardiac interstitium or by binding to cardiac cells, and prorenin is activated to renin in cardiac cells. 21 Ang II binds primarily to Ang II type 1 receptor (AGT1R) to promote cell growth and hyper trophy. Ang II also stimulates to aldosterone synthase (CYP11B2) for the synthesis and release of aldosterone, which promotes fluid retention and cardiac fibrosis. 22 The presence of common genetic variants, or polymorphisms, in all these genes can modify RAAS activation and/or receptor function. 5 The aim of the present systematic review is to summa rise and clarify the findings obtained in several studies about the role of different polymorphisms identified to date in the RAAS in patients with HCM to give some insights into the possible impact of these polymorphisms on the phenotypic manifestations of the disease.
Methods
Published data for this review were identified by search and selection in the MEDLINE database and reference lists from relevant articles and reviews. A twostep approach was used. First, genetic polymorphisms were identified in a search with the keywords 'hypertrophic cardiomyopathy' and 'polymorphism'. Second, polymorphisms that were identified with this search and related with the RAAS were used as keywords with the addition of the following key words: 'hypertrophic cardiomyopathy', 'cardiomyopathy', 'left ventricular mass', 'left ventricular hypertrophy' and 'fibrosis'. Bibliographies of all selected articles and review articles about HCM and/or RAAS polymorphism were reviewed for other relevant articles.
Physiopathology of hypertrophic cardiomyopathy
While the aetiology of HCM has been extensively studied, its pathogenesis is not completely understood. 23 In vitro functional studies have shown that HCM mutants alter sar comere function either by decreasing the translocating fila ment activity and/or force, leading to a reduction of power production. It can also increase in vitro motility rates of filament sliding and/or force. 24 It is not well understood how a mutation of a sarcomeric protein and the develop ment of the microscopic characteristics of HCM are linked. Some of the mutations identified in the sarcomeric proteins have been observed to reduce myocyte contractility, while others increase the force of contraction. 25 The hypothesis that can explain the hyper and hypocontractility observed in both previous models is the 'energy compromise' hypoth esis. 26 Briefly, in patients with HCM, there is a reduction of the phosphocreatine to ATP ratio, which is an indicator of the energetic state of cardiac muscle. Such inefficient utili sation of ATP results in the need for more energy to produce the same amount of force. Support for this hypothesis comes from the study of other human diseases that limit myocardial energy production or cellular energy homeosta sis, such as mitochondrial tRNA mutations 27 or Friedreich's ataxia, 28 as commented before.
HCM is clinically characterised by left ventricular hyper trophy (LVH) in the absence of another cardiac or systemic disease that is capable of producing significant wall thick ening. Other morphological and histological features of HCM include interstitial fibrosis, thickening of the media of intramural coronary arteries, abnormal positioning of the mitral valve annulus, and elongated mitral leaflets, among others. 10 All these features promote that patients with HCM typically have left ventricular diastolic dysfunction due to increased chamber stiffness and impaired relaxation, which prevents increase in exercise stroke volume and cardiac out put. 29 The left ventricular size is closely related to the size of left atrium and left ventricular enddiastolic pressure. 30 Thus, the severity of left ventricular diastolic dysfunction may be another factor for atrial fibrillation that occurs in 20% of HCM patients. 31, 32 Although hypertrophy and fibro sis are the common responses of the heart to all forms of injury, myocyte disarray is considered the pathological hall mark of HCM and often comprises more than 20% of the ventricle. 33 The extent of disarray does appear to be associ ated with a more malignant course in younger patients with HCM, as severe myocardial fibrosis appears to promote premature deaths from heart failure and an increased risk of primary ventricular arrhythmias. 34 Indeed, the incidence of stroke is around 3% per patientyear, especially in patients with HCM and atrial fibrillation, or those with obstructive HCM. 35 Thromboembolic events are frequent and poten tially serious causes of mortality and morbidity among HCM patients. Ultimately, about 10% of patients with HCM progress to an endstage dilated phase with left ventricular wall thinning, cavity enlargement, and systolic dysfunction that resembles a dilated cardiomyopathy. 36 In common multifactorial diseases, such as HCM, the candidate gene approach is widely used to study genetic polymorphisms. This allows for the identification of gene defects directly involved in the physiopathology of HCM (susceptibility genes), or variants involved in modification of its phenotypic expression (modifier genes). Moreover, the diverse phenotypic expression observed between unre lated families, or even among affected individuals from the same family, continues to raise intriguing questions about genetic penetrance and the impact of additional factors. 37 Polymorphisms of the RAAS represent an attractive hypothesis as potential disease modifiers as these genetic variants alter the 'activation status' of the RAAS, which leads to more LVH and left ventricular remodelling through different pathways. 17, 18, 3843 
RAAS polymorphisms
Angiotensin-converting enzyme ACE is a membranebound enzyme which is located in vas cular endothelial cells and is widely distributed in the body, converts Ang I to active Ang II and inactivates a vasodilator and natriuretic peptide bradykinin. Ang II, the end product of the renin-angiotensin system, is a potent vasopressor peptide, which also has cellgrowthpromoting or modulat ing features. 44 Local synthesis of Ang I and II is utilised in the heart muscle, 45 and ACE is increased in level and activ ity in hypertrophied heart muscle. 46 The ACE gene in humans has been identified and cloned. It is a single 21 kb, 26 exon gene at the 17q23 locus of the human genome. 47 More than 100 polymorphisms have been identified at the ACE locus. 48 The variability in the levels of ACE in different individuals led to the identification of the most popular polymorphism in the ACE gene based on the presence (insertion, I) or absence (deletion, D) of a 287 base pair DNA fragment that accounted for 47% of the total variability in the serum ACE level. 49 The restriction frag ment length polymorphism is located inside intron 16 of the ACE gene and corresponds to an Alu repetitive sequence. Compared with the II genotype, ACE activity was highest in DD homozygotes and intermediate in ID heterozygotes. In one metaanalysis 50 of 145 studies on the D/I polymor phism of the ACE gene, the overall prevalence of the D allele in 49,959 subjects amounted to 54.0%. The DD, DI and II genotype frequencies were 30.5%, 47.0% and 22.5%, respectively. Race was a major determinant of the D and I allele frequencies. The prevalence of the D allele was 56.2% in Caucasians, higher (p < 0.001) in blacks (60.3%), but substantially lower (p < 0.001) in Asians (39.1%).
A large number of studies have explored the association of the I/D polymorphism with expression of the clinical phenotypes in HCM. 17, 18, 5153 The first study on the ACE polymorphism and HCM showed that the DD genotype was more common in HCM families with a high incidence of sudden cardiac death (SCD) as compared with those with a low incidence of SCD. 51 Subsequent studies provided fur ther evidence of the modifying effects of the ACE1 gene by showing an association between the I/D genotypes and the severity of HCM. 52, 53 Indices of cardiac hypertrophy, such as the mean interventricular septal thickness, the mean left ventricular mass index (indexed to body surface area), and a semiquantitative index of LVH, called the Wigle score, were greater in HCM patients with the DD genotype as compared with others. 17, 18, 54 Moreover, the DD genotype appears to be related to adverse effects in regard to ischae mic or idiopathic dilated cardiomyopathy, and cardiac hypertrophy and remodelling. 55 On the other hand, a study of the impact of ACE on HCM did not detect an association between ACE genotypes in a Japanese population. 56 Also, a further study in 104 Dutch patients did not support a role for the I/D polymor phism as a modifier in this disease. 41 Another largescale investigation was performed in the Framingham Heart Study in 2439 subjects, 57 finding no association between ACE genotypes and echocardiographic LVH. One explana tion for these conflicting results could be that the associa tion of the ACE I/D genotype with the expression of cardiac hypertrophy is dependent on the causal mutation, and a sig nificant association is present in those with the R403Q mutation in the βmyosin heavy chain but not in others. 17 However, the presence of polymorphisms in the RAAS contributes toward the development of myocyte hypertro phy independent of filament mutation status. 58 The polymorphism 4656(CT)2/3 has been also identi fied in the ACE. It depends on a repetition of two or three CT nucleotides. The 4656(CT)2/3 polymorphism was asso ciated with serum ACE levels. 59 However, this polymor phism has not yet been found to be associated with any cardiovascular disease.
Angiotensinogen
Angiotensinogen is an α2globulin that is produced consti tutively and released into the circulation mainly by the liver. Human angiotensinogen is 452 amino acids long, but the first 12 amino acids are the most important for activity. Renin catalyses the cleavage of angiotensinogen to the decapeptide angiotensin I. 11 In humans, the angiotensinogen gene is located on chro mosome 1q42-43 and comprises five exons and four introns spanning 12 kb. 60 More than 20 molecular variants have been identified. 61 Of these, three polymorphisms have been studied more extensively: two mutations in exon 2, the first a substitution of 704T>C resulting in a methionine to threo nine exchange at position 235 (M235T), the second a threo nine to methionine substitution at position 174 (T174M); and the third polymorphism is a guanine to adenine substitu tion 6 bp upstream from the initiation site of transcription in the promoter region (-6G>A). 61 This last variant is in close linkage disequilibrium with the M235T polymorphism and, therefore, these will be discussed together. As the T174M variant has been observed only once related with LVH, 62 we will focus on the M235T polymorphism.
In a metaanalysis including 69 studies, the overall prevalence of the C allele (235T amino acid) was 52.1%. 63 The CC, CT and TT genotype frequencies were 30.6%, 42.9% and 26.5%, respectively. The prevalence of the C allele was dependent on race (p < 0.001), being 77.0% in blacks, 78.0% in Asians, but only 42.2% in whites. The presence of the C allele is associated with higher levels of angiotensinogen. 64 In HCM, conflicting findings have been published. In Japanese subjects, one study revealed a higher frequency of the 235T amino acid in HCM. 37 A study by Ortlepp and col leagues in 26 family members carrying a single mutation in the MyBPC gene revealed a significant association between the angiotensinogen polymorphism and cardiac hypertrophy. 17 Moreover, studies in Chinese, 65 South Korean 66 and Japanese patients 67 found an association between the CC genotype and cardiac hypertrophy. In con trast, the extent of hypertrophy in 108 unrelated Canadian patients was not influenced by angiotensinogen genotype. 40 Others studies in Caucasians did not find any significant association between M235T and cardiac hypertrophy. 61, 68 This could suggest a more important role for the M235T polymorphism in Asian populations, perhaps related to a higher frequency of the C allele in these populations. 69 
Angiotensin II type I receptor (AGTR1)
The final effector of the RAAS is Ang II, which exerts most of its known cellular actions through the AGTR1. Stimulation of the AGTR1 results in vasoconstriction, increased atherogenesis, inflammation, growth, prolifera tion or coagulation, depending on local conditions. 70 The human AGTR1 gene, located on chromosomes 3q21-3q25, consists of five exons and four introns and leads to four distinct alternatively spliced transcripts, the relative abundance of which varies from one tissue type to another. 71 More than 20 polymorphisms have been identi fied and none of them alter the amino acid sequence of the encoded protein, being the nucleotidic change in the 3′ untranslated region 1166A>C, the polymorphism that has been most extensively studied in the literature. 48 The overall frequency of the C allele in 13 studies with 4332 subjects was 25.7%. 72 The prevalence of the C allele (28.8% vs. 9.2%), CC homozygosis (7.7% vs. 1.1%), and CA heterozygosis (42.1% vs. 16.2%) were significantly higher in Caucasians than Asians (p < 0.001). The C allele has been associated with LVH, 73 myocardial infarction, 74 progression of diabetic nephropathy 75 and HCM. 17, 18, 41 In a study of 104 genetically independent subjects with HCM, the C allele was associated with a higher LV mass (p = 0.01). 41 Moreover, Ortlepp et al. 17 showed that the 1166C allele might adversely affect the phenotypic expres sion of HCM. In another study, the C allele was associated with a greater left ventricular wall thickness, intraventricu lar septum, and LV mass index (p < 0.05) in normotensive subjects but not in hypertensive patients. 73 Recently, one biochemical mechanism has been elucidated by which the 1166A>C polymorphism in the AGTR1 can possibly lead to RAAS activation and thus be a risk factor for HCM, among other cardiovascular diseases. 76 This polymorphism occurs in a cisregulatory site, which is recognised by a specific microRNA, miR155. When the 1166C allele is present, basepairing complementarity is interrupted, and the ability of miR155 to interact with the cisregulatory site is decreased. As a consequence, miR155 no longer attenuates translation, resulting in increased AGTR1 densities. 76 Another study has identified polymorphisms located in the coding or the 3' and 5' flanking region of the AGTR1 gene. 71 Of these identified polymorphisms, only 573C>T was in complete linkage disequilibrium with 1166A>C. 71 Although this singlebase polymorphism is in the coding region of the gene, the mutation at this site does not alter the amino acid sequence of the encoded protein. Furthermore, none of the newly identified polymorphisms (including the singlebase change at nucleotide 573C>T) have been asso ciated with HCM findings.
Angiotensin II type 2 receptor (AGTR2)
Ang II has multiple actions in the heart, most of which can be attributed to activation of the AGTR1, but cardiac cells also express a second Ang II receptor, namely the AGT2 receptor (AGTR2), which differs from AGTR1 with regard to expression and mode of desensitisation. 77 AGTR2 block ade amplifies the early signs of the cardiac growth response to Ang II in rats and partially negates antihypertrophic effects of AGTR1 blockade on pressureoverload rat car diac hypertrophy. 78 Initially, it was thought that AGT2Rs are widely expressed in the foetal heart and disappear after birth, to return only under pathological conditions. 79 More recent studies in adult animals, however, have shown that this may not be true and that AGTR1 and AGTR2 are expressed in the heart, with AGTR1 predominating under normal conditions. 80, 81 In addition, it has been observed that in the human heart, under pathological conditions, AGT2Rs are upregulated, 80, 81 although their effects in man are cur rently unknown.
The human AGTR2 gene is localised on chromosome X (Xq22), which is of importance when one considers a possi ble gender effect of mutations or polymorphisms. 82 The most important polymorphism of AGTR2 that has been associated with HCM is the polymorphism in the 3' untranslated region of exon 3 (3123A>C) of this gene. The frequency of the A allele, considered as the risk one, in a study with 103 geneti cally independent subjects with HCM was 0.45. 20 In this study, the association between the 3123A>C polymorphism in exon 3 of the AGTR2 gene and extent of hypertrophy was investigated. The extent of echocardiographic hypertrophy decreased with the number of C alleles in women. 20 Moreover, a potential interaction between AGTR1 1166A>C and AGTR2 3123A>C polymorphisms was detected in men only. It was observed that intraventricular septum thickness, left ventricular mass index, Wigle score, and plasma renin in women decreased in parallel with the number of C alleles in women. 20 Peak left ventricular outflow tract gradient was higher in women carrying the C allele. All these observations suggest that the Ang IImediated effects on cardiac mass appear to be the result of a balance between AGTR1 and AGTR2, in a genderspecific manner, in that the AGTR1 C allelerelated proLVH effect is observed in men carrying the AGTR2 A allele only, whereas the AGTR2 C allelerelated antiLVH effect is observed in women, irrespective of their AGTR1 genotype. 20 
Aldosterone synthase (CYP11B2)
Aldosterone secretion is regulated primarily by the reninangiotensin system. 83 It is synthesised from deoxycorti costerone by a mitochondrial cytochrome P450 enzyme, aldosterone synthase (CYP11B2). 84 Aldosterone can directly induce myocardial cell hypertrophy via activation of the mineralocorticoid receptors, a member of the steroid/ thyroid/retinoid nuclear receptor family of liganddependent transcription factors. 85 Therefore, genetic variations in the regulation of aldosterone synthesis might influence the structure and function of the left ventricle. 86 The corresponding gene for this enzyme is located on chromosome 8, band 8q22. Aldosterone, like Ang II, can be produced in the heart, particularly in individuals with HCM because their cardiac aldosterone synthase (CYP11B2) mRNA levels are increased sevenfold as compared with age and gendermatched normal donor hearts. 86 Several frequent polymorphisms have been described in the transcriptional regulatory region and the second intron of CYP11B2. 87 However, only two of these polymorphisms have significant associations with left ventricular size, mass, and function in an agehomogeneous population sample with a low prevalence of cardiovascular diseases. 42 The first is located in the transcriptional regulatory region, or promoter, of CYP11B2, 344 nucleotides before the start of the protein coding sequence. This position can be either a cytosine or thymidine (-344C>T). The second polymorphism is located in the second intron of CYP11B2 and is a gene conversion of this intron with the gene 11βhydroxylase (CYP11B1). 42 However, the -344C>T promoter polymorphism is a much better predictor of left ventricular size than is the intron 2 gene conversion polymorphism. 42 The allele frequencies of the promoter polymorphism are C 0.42 and T 0.58. 17, 18, 68 The role of this polymorphism in the development of HCM has been observed in many studies in adult patients, 17, 18, 86, 8890 but not in all. 46, 68 Upregulation of this enzyme was associated with increased aldosterone produc tion, which promotes myocardial fibrosis. 88 Progressive myocardial fibrosis would result in progressive ventricular remodelling and hypertrophy, which could provide a poten tial mechanism for the progressive septal hypertrophy and the increase in ventricular mass seen in these patients.
Moreover, in a study with a relatively young and homogene ous population for age and almost completely free of hyper tension and other cardiovascular disease, it was shown that polymorphic variations in the CYP11B2 gene were associ ated with left ventricular size, mass, and diastolic function in persons free of clinical cardiovascular disease. 42 There are conflicting data about this polymorphism in the literature. For most authors, the risk allele is the -344C, 5, 17, 18, 42, 68, 89 although for some others, the risk allele found was -344T 90 . However, in the latter, when all sub jects were analysed together, no genotype showed any sig nificant differences regarding all of the measured parameters, and only when the study population was subdi vided according to gender was intraventricular septum thickness significantly higher in men carrying one or two T alleles than in male CC homozygotes. In addition, when female patients were analysed, the authors found contradic tory results when comparing with males (i.e. intraventricu lar mass thickness, left ventricular mass index and Wigle score were higher in CC women vs. CT+TT women); these discrepancies were explained as being due to the low number of CC women in the study and the presence of one CC woman with an exceptionally large heart.
Supporting the role of -344C as the risk allele, it has been found that the -344 position in the CYP11B2 pro moter is immediately adjacent to a binding site for a tran scription factor, SF1, that is thought to be essential for expression of steroid biosynthetic enzymes in the adrenal cortex. 91 In vitro, the -344C allele binds SF1 approxi mately four times more strongly than does the -344T allele, which is consistent with an effect on higher expression of CYP11B2. 42 
Cardiac chymase A (CMA)
Ang II production in the heart can be attributed not only to ACE but also to a serin protease named heart chymase (CMA). 54 This protein was cloned for the first time, from human heart, in 1991. 92 The relationship of this protease with the extent of LVH in patients with HCM, and the evi dence that it may account for 80% of Ang II generated in the human ventricle, 92 suggests that CMA is associated with increased local Ang II generation.
The existence of two different polymorphisms in the human chymase gene was reported for the first time in 1996. 38 The first polymorphism, termed CMA/A was a 1625G>A transition in the second intron. This polymor phism was neither related to susceptibility to HCM nor influenced its phenotypic expression. Moreover, when a twolocus analysis was carried out between ACE I/D and CMA/A genotypes, no statistically significant relationship was found with HCM. 38 The second polymorphism, named CMA/B was a -1903G>A transition in the 5' untranscribed region of the CMA gene. The allele frequencies of the CMA/B polymorphism were A 0.53 and G 0.47, 17 A being the risk allele. These frequencies are very similar to those obtained by other authors. 18, 36 In some studies, when the CMA/B polymorphism (-1903G>A) was analysed alone, the differences in left ventricular mass between patients and controls did not reach statistical significance. 38, 54, 58 However, in a family study, 17 HCM patients with the CMA/B AA polymorphism had a significantly greater degree of LVH than controls in a univariate analysis, and showed a clear trend towards sig nificance in a multivariate analysis. 17
Effect of several pro-LVH RAAS polymorphisms
The synergistic effect of several polymorphisms of the RAAS system in HCM has been analysed extensively in the literature. 5, 17, 38, 54, 93 In the latter, it was found that patients with the deletion in the ACE gene and C allele in AGTR1 gene had lower ejection fractions and increased left ven tricular mass. 93 Furthermore, it has been observed, in a novel study, that the presence of these two polymorphisms together causes an increase in RAAS activity, which is closely related to myocardial hypertrophy and subsequent left ventricular remodelling. 94 However, these results were not confirmed by one study in Caucasians. 39 On the other hand, the impact of six proLVH polymorphism in RAAS (ACE deletion, AGT M235T, AGT T174M, AGTR1 A1166C, AGTR2 A3123C, CYP11B2 -344C>T and CMA B -1903G>A) in the appearance of fibrosis in patients with HCM was tested. The amount of fibrosis was not associated with myofila ment-HCM genotype status or polymorphisms in the RAAS cascade, 95 possibly as a result of the low number of patients (n = 59). Nevertheless, there was a trend toward more fibro sis in patients with ≥ 1 Cencoding allele in CYP11B2 encoded aldosterone synthase (p = 0.06). 95 This observation was in correlation with another study investigating five RAAS gene polymorphisms and their influence in the pro gression of paediatric HCM, where the CYP11B2 polymor phism was associated with the strongest effect. 5 In other studies, when patients carrying previously iden tified 'risk genotypes' of the RAAS were analysed together, patient groups proved to have a significantly higher left ven tricular mass index than did the controls. 17, 18, 38, 54 In a multi variate model with other factors possibly influencing LV mass, a significant association was still present. 54 It would be plausible to speculate that each of these markers exerts a modest effect on left ventricular mass, but this effect is more fully potentiated when 'risk genotypes' are present.
Limitations and future perspectives
As discussed before, there is a huge discrepancy in the results from different studies regarding the effect of several RAAS polymorphisms in HCM. Some of the explanations for the variability of the data obtained are: (i) lack of power to detect the typically small effects in genetic association studies of multifactorial traits; 96 (ii) heterogeneous patient populations in most studies; 17 (iii) small studies with statis tically significant associations are more readily published, thus overestimating the true effect; 89 and (iv) several stud ies used unconditional statistical methods for data analysis, despite the fact that they matched their cases and controls on population characteristics. 38, 97, 98 This may underesti mate the effect of the polymorphisms studied, as it will bias the results toward the null hypothesis. 89 Polymorphisms in the RAAS have been associated with progressive septal hypertrophy and increased sever ity of left ventricular outflow obstruction, both of which are risk factors for poor outcomes including risk for sud den death. 5 As the inhibitors of the RAAS have proven its anti hypertrophic and antifibrotic effects in acquired cardiac diseases, 99 the potential beneficial effects of treatment with different AGT1R blockers in mouse HCM models have been investigated. 100, 101 The results show that treatment with losartan reversed interstitial fibrosis in a genetic mouse model of HCM, a finding that raised the possibility of new therapeutic options for human HCM and supports the hypothesis that interstitial fibro sis, a major predictor of SCD in HCM, is a secondary phenotype that may be reversed. 100 However, to date the results in human studies, although preliminary, have been unsatisfactory.
Conclusion
Genetic studies of the components of the RAAS have pro duced evidence that several genetic polymorphisms, acting alone or in concert, may influence the phenotypic changes observed in HCM. A role for these polymorphisms as modi fier, rather than susceptibility, genes seems more likely considering the evidence so far, suggesting that RAAS pol ymorphisms may form a pool of factors that individually or collectively contribute to LVH. 17 In addition to the need for larger studies to examine the effects of single genetic vari ants and haplotypes, future studies are also needed to focus on the complexity of these systems and study gene-gene and gene-environment interactions. 99
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